Telomir Pharmaceuticals Joins BIO Convention for Partnerships

An announcement from Telomir Pharmaceuticals, Inc. ( (TELO) ) is now available.

On June 2, 2025, Telomir Pharmaceuticals announced its participation in the BIO International Convention 2025 to explore potential partnerships and M&A opportunities. The company is advancing its lead candidate, Telomir-1, towards an IND submission by year-end, with plans for first-in-human trials in 2026. Significant preclinical progress was reported, including promising results in retinal regeneration, lifespan extension, diabetes reversal, and cancer treatment. Telomir is also launching a rare disease initiative and exploring broader applications for Telomir-1.

The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.

More about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing novel therapeutics aimed at elongating telomeres, regenerating cells, and reversing biological aging. The company is also involved in rare disease development, targeting orphan indications such as Werner’s syndrome, Wilson’s disease, Progeria, and dysphonia.

Average Trading Volume: 168,485

Technical Sentiment Signal: Sell

Current Market Cap: $57.89M

Learn more about TELO stock on TipRanks’ Stock Analysis page.